Biotechnology · Sarasota, Florida, United States
$1.22
-13.64% (-$0.19)2026-10-13
Revenue$0
Net Income-$832.8K
EPS$-2.46
Market Cap$1.4M
Price Performance
Historical data including institutional events
Company Profile
E
Eric Weisblum
CEO & Executive Director
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The companyâs lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the companyâs two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimerâs disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The companyâs research and development programs are conducted through collaborations with Columbia University, Medspray Pharma BV, and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
- Founded
- 2010
- Employees
- 3
- Headquarters
- Sarasota, Florida, United States
- Website
- silopharma.com
Peer ComparisonRevenue ($B)
▾Loading company sections...